With many clinical sites shut down to enforce social distancing and trial staff diverted to duties related to COVID-19, some life sciences companies have begun conducting decentralized clinical trials (DCTs). These studies use new technology and processes to perform many trial functions remotely rather than at the site, and rely on help from the patient, family members and other caregivers instead of healthcare professionals.
The shift to DCTs has also helped address weaknesses in the traditional clinical trial model that predate the pandemic. These include:
However, DCT adoption has been limited by many forces, including trial sponsor inertia, uncertainty about regulatory approval and unreliable remote sensing and reporting technology. Adoption has also been hampered by the fact that study protocols are written for clinicians, not patients, making it more difficult for participants to follow treatment regimens, report on their condition and give informed consent to the trials without visiting a professional.
Continued COVID-19 restrictions on face-to-face contact, however, forced rapid adoption of DCTs despite these early issues. At the same time, regulators clarified DCT requirements, and new remote monitoring capabilities such as electrocardiogram sensing in products (i.e., an Apple Watch Series 6) continue to make DCTs more feasible.
This is an opportunity to not only continue lifesaving clinical trials during this and future pandemics, but also to transform the trial experience for study participants. DCTs reduce the need for inconvenient travel for patients, empower participants and caregivers to administer treatment, monitor results and make needed interventions, and facilitate the real-time gathering of clinical information and the delivery of clinical trial supplies.
Most importantly, DCTs can reduce the time, cost and effort of clinical trials and speed the delivery of new treatments to market.
Deciding where and how to begin the journey to DCTs can seem daunting. A clinical trial assessment and prioritization framework can help determine which trials are best suited to decentralization, which technologies and processes are needed to make them successful, and how to create a plan for initiating decentralized trials most quickly.
We suggest following a framework that includes first evaluating the potential patient consequences -- ranging from fatal to severe to major, minor, or none — of discontinuing or delaying each trial. For those trials where the consequences of delay are most fatal or severe or major, the next step is to examine the study protocol to assess test requirements including:
The weight assigned to each metric will vary based upon the type of condition involved. For example, complex oncology treatments that require infusions and a routine scan or cardiology treatments that require advanced diagnostics or expert skill may be less suitable for remote trials than a behavioral or respiratory condition that can be monitored without the need for expert help.
Such a framework should then walk the user through a detailed series of questions (see interactive version) to help determine which trials are best to decentralize and how to best to implement them.
This accelerated move to a more digital process can bring sustainable benefits even after the current pandemic ends. Enabling more online and home-based monitoring and intervention can bring benefits in areas such as:
Begin the move to DCTs by assessing the number and types of trials now underway using a clinical trial assessment and prioritization framework. Next, identify the obstacles to moving the most likely candidates to a decentralized model. Then, carefully examine the study protocol and reimagine how interventions now performed onsite could be done digitally. This could involve customizing existing digital tools and applications as well as creating new interfaces to meet the needs of the study protocol. It may also include working with regulators and review boards to secure approval for needed changes to protocols and trial plans.
Then move to rapid implementation of the DCT, adopting modern techniques such as Agile development, and continuously refine based on insights and user feedback. Successful implementation of DCTs also requires careful attention to logistical details such as the ability to ship the right mix of medication and supplies to each patient when they need them. If executed with an experienced partner, and a sense of urgency, an organization’s first decentralized trials can be underway in as little as three to four months.
Even when the current pandemic ends, there is no reason for clinical trials to return to their traditional manual, labor-intensive form. By using modern digital technology, companies can empower patients and caregivers, improve patient care and continue to deliver new therapies to the market if and when another pandemic occurs.
To learn more read Making Decentralized Trials Work: Three Must Haves, visit the Life Sciences section of our website or contact us.
This article was written by Bryan Hill, Pratik Maroo, Venu Mallarapu and Vidya Viswanathan of Cognizant’s Life Sciences practice.